# Study to Evaluate the Safety of Nanoxel M Inj.

> **NCT04066335** · — · UNKNOWN · sponsor: **Samyang Biopharmaceuticals Corporation** · enrollment: 1498 (estimated)

## Conditions studied

- Breast Cancer
- Non-small Cell Lung Cancer
- Prostate Cancer
- Ovarian Cancer
- Head and Neck Cancer
- Gastric Cancer
- Esophageal Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04066335
- **Lead sponsor:** Samyang Biopharmaceuticals Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-18
- **Primary completion:** 2024-08
- **Final completion:** 2024-08
- **Target enrollment:** 1498 (ESTIMATED)
- **Last updated:** 2019-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04066335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04066335, "Study to Evaluate the Safety of Nanoxel M Inj.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04066335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*